SHIEF Company Profile and Key Details

Shield Therapeutics plc earnings surprise history is a mixed track record. The quarter that ended April 24, 2025, missed forecasts by -17.13%.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

The stock is currently mid-range between its 52-week high and low $0.05 and $0.17. With a market capitalization of about $91.55 million, Shield Therapeutics plc is classified as a micro-cap and shows higher-than-market volatility (beta ~1.72). Key stats such as the average daily volume over the past year has been around 34.56 thousand shares, volume is running light vs its 52-week average. Headquartered in Gateshead, GH, Shield Therapeutics plc operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Anders Lundstrom, the company employs approximately 61 people and listed since December 06, 2019. Shield Therapeutics plc operates as a specialized pharmaceutical firm, dedicated to developing and bringing to market advanced clinical therapies that address significant unfulfilled medical requirements.

Our AI price prediction model suggests that Shield Therapeutics plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Valuation shows Shield Therapeutics plc trading at a premium to the broader market with a P/E of -8.73.

Shield Therapeutics plc trades at a P/E ratio of -8.73, slightly below the S&P 500 average, with a price-to-sales ratio of 1.57 and a price-to-book ratio of -5.38 indicating negative book value, which may reflect financial stress. The P/FCF stands at -7.42, also below market averages.